IDYA
Price
$33.14
Change
-$0.57 (-1.69%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.9B
131 days until earnings call
Intraday BUY SELL Signals
RNA
Price
$70.90
Change
+$0.05 (+0.07%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
10.68B
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs RNA

Header iconIDYA vs RNA Comparison
Open Charts IDYA vs RNABanner chart's image
IDEAYA Biosciences
Price$33.14
Change-$0.57 (-1.69%)
Volume$9.83K
Capitalization2.9B
Avidity Biosciences
Price$70.90
Change+$0.05 (+0.07%)
Volume$17.04K
Capitalization10.68B
IDYA vs RNA Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
RNA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. RNA commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (IDYA: $33.13 vs. RNA: $70.89)
Brand notoriety: IDYA and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 78% vs. RNA: 51%
Market capitalization -- IDYA: $2.9B vs. RNA: $10.68B
IDYA [@Biotechnology] is valued at $2.9B. RNA’s [@Biotechnology] market capitalization is $10.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, both IDYA and RNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • RNA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than RNA.

Price Growth

IDYA (@Biotechnology) experienced а +3.69% price change this week, while RNA (@Biotechnology) price change was +0.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

RNA is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($10.7B) has a higher market cap than IDYA($2.9B). RNA YTD gains are higher at: 143.776 vs. IDYA (28.911). IDYA has higher annual earnings (EBITDA): -380.2M vs. RNA (-518.74M). RNA has more cash in the bank: 1.18B vs. IDYA (670M). RNA has less debt than IDYA: RNA (5.14M) vs IDYA (26.6M). RNA has higher revenues than IDYA: RNA (10.7M) vs IDYA (7M).
IDYARNAIDYA / RNA
Capitalization2.9B10.7B27%
EBITDA-380.2M-518.74M73%
Gain YTD28.911143.77620%
P/E RatioN/AN/A-
Revenue7M10.7M65%
Total Cash670M1.18B57%
Total Debt26.6M5.14M518%
FUNDAMENTALS RATINGS
IDYA: Fundamental Ratings
IDYA
OUTLOOK RATING
1..100
17
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
60
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IDYARNA
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
RNA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VFMO182.910.95
+0.52%
Vanguard US Momentum Factor ETF
DHSB25.69N/A
N/A
Day Hagan Smart Buffer ETF
EVSB51.05-0.01
-0.02%
Eaton Vance Ultra-Short Income ETF
PUI45.12-0.02
-0.05%
Invesco Dorsey Wright Utilities Momt ETF
RIFR25.82-0.20
-0.78%
Russell Inv Global Infrastructure ETF

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.72%
NUVL - IDYA
59%
Loosely correlated
+2.71%
NRIX - IDYA
58%
Loosely correlated
+13.09%
XENE - IDYA
58%
Loosely correlated
+0.15%
OCUL - IDYA
57%
Loosely correlated
+2.81%
IMTX - IDYA
57%
Loosely correlated
N/A
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+0.06%
DYN - RNA
63%
Loosely correlated
-1.67%
IDYA - RNA
50%
Loosely correlated
-1.72%
ACLX - RNA
49%
Loosely correlated
-0.38%
CRNX - RNA
48%
Loosely correlated
-0.23%
DSGN - RNA
48%
Loosely correlated
-3.03%
More